Oh, David Y.

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

Oh, D. Y., Kwek, S. S., Raju, S. S., Li, T., McCarthy, E., Chow, E., Aran, D., Ilano, A., Pai, C.-C. S., Rancan, C., et al. (2020) · Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 734

Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox

Oh, D. Y., & Fong, L. (2021) · Immunity

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 467

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

Oh, D. Y., Cham, J., Zhang, L., Fong, G., Kwek, S. S., Klinger, M., Faham, M., & Fong, L. (2017) · Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 236

Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade

Pai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 141

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

Aggarwal, R., Starzinski, S., de Kouchkovsky, I., Koshkin, V., Bose, R., Chou, J., Desai, A., Kwon, D., Kaushal, S., Trihy, L., et al. (2023) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 104